SCHEMBL880272

SCHEMBL880272

CCc1ccc(C2CC(=O)Nc3c2ccc2ccccc32)cc1

nearest known ligand 0.62

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.62
ALDH1A1 P00352 3/20 0.59
MAPK1 P28482 1/20 0.59
TDP1 Q9NUW8 1/20 0.59
SMN1; SMN2 Q16637 3/20 0.57
MAPT P10636 3/20 0.57
HTT P42858 1/20 0.57
KMT2A Q03164 1/20 0.57
HSD17B10 Q99714 1/20 0.57
IDO1 P14902 2/20 0.48
TP53 P04637 5/20 0.47
POLB P06746 1/20 0.47
KDM4E B2RXH2 1/20 0.45
THRB P10828 1/20 0.42
GAA P10253 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL880388 0.86 LMNA (0.66) LMNAALDH1A1MAPK1TDP1SMN1; SMN2
SCHEMBL852442 0.86 LMNA (0.72) LMNAALDH1A1MAPK1TDP1SMN1; SMN2
SCHEMBL880430 0.84 LMNA (0.67) LMNAALDH1A1MAPK1TDP1SMN1; SMN2
SCHEMBL880450 0.84 LMNA (0.66) LMNAALDH1A1MAPK1TDP1SMN1; SMN2
SCHEMBL880425 0.83 LMNA (0.62) LMNAALDH1A1MAPK1TDP1SMN1; SMN2
SCHEMBL10280289 0.83 LMNA (0.62) LMNAALDH1A1MAPK1TDP1SMN1; SMN2
SCHEMBL880271 0.83 LMNA (0.62) LMNAALDH1A1MAPK1TDP1SMN1; SMN2
SCHEMBL14095231 0.81 LMNA (0.57) LMNAALDH1A1MAPK1TDP1SMN1; SMN2
SCHEMBL10280365 0.81 LMNA (0.66) LMNAALDH1A1MAPK1TDP1SMN1; SMN2
SCHEMBL880490 0.81 LMNA (0.62) LMNAALDH1A1MAPK1TDP1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8440705-B2 2,3,4,7,8,9-hexahydro-1H-cyclopenta[h]quinolin-2-one or 2,3,4,6,7,8-hexahydro-1H-cyclopenta[g]quinolin-2-one; Alzheimer's disease WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2013-05-14 US disclosed
EP-2433634-A2 Compounds, compositions and methods of inhibiting a-synuclein toxicity The Whitehead Institute for Biomedical Research (US) 2012-03-28 EP disclosed
US-20080261953-A1 Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261953-A1 Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity SNCA, PARK7, HTT LMNA 525/4885ALDH1A1 171/4885MAPK1 2847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.